Articles tagged with Glioblastomas
A new study funded by The Ben & Catherine Ivy Foundation has identified propentofylline as a potential drug that could help treat glioblastoma multiforme (GBM), a deadly brain tumor. The research found that PPF can limit the spread of GBM and increase the effectiveness of chemotherapy drugs and radiation therapy.
Researchers at University of California - San Diego developed a new computational strategy to search for molecules that could inhibit glioblastoma growth. One molecule, SKOG102, successfully shrunk human glioblastoma tumors grown in mouse models by an average of 50 percent.
A study found that low BRCA1 protein expression in glioblastoma tumors correlates with longer overall survival, suggesting a potential predictive biomarker for treatment responses to DNA-damaging therapies.
A team of researchers has mapped the connections between genetic mutations and protein regulation in glioblastoma multiforme (GBM) brain cancer. They found that targeting specific transcription factors, such as SOX9 and FOXG1, could potentially treat GBM using BET bromodomain inhibitors.
A Phase 2 clinical trial found that gene therapy VB-111 increased overall survival to 15 months, compared to 8 months for those receiving chemotherapy Avastin alone. The therapy effectively starves tumors by blocking new blood vessel growth and is safe and well-tolerated.
Scientists at Van Andel Research Institute and University of Toledo have discovered a way to stop the spread of glioblastoma multiforme by activating a family of proteins. This innovative approach may lead to a novel treatment for this deadly brain cancer, which affects 22,000 people in the US each year.
Researchers have developed a new therapy that slows the spread of deadly brain tumor cells by disrupting their communication pathway. The treatment improved patient survival by 50% in a mouse model and has potential as an adjunct to traditional chemotherapy and radiation treatments.
Researchers found an enzyme called LSD1 turns off genes required to maintain cancer stem cell properties in glioblastoma. Drugs modifying LSD1 levels could provide a new approach to treating the disease.
V-Smart Nanomedicine for glioblastoma multiforme (GBM) will target and deliver a known chemotherapeutic across the blood brain barrier, providing an effective new treatment option. The grant supports the development of this transformative therapeutic for brain cancer patients.
A national cancer study has found that a tumor's DNA, not just tumor stage, is key to determining if a lower-grade malignant brain tumor may rapidly progress to glioblastoma. The findings could lead to earlier and more aggressive treatment for those tumors projected to be on the fast path.
The Ivy Glioblastoma Atlas Project provides valuable resources for researchers to find cures for aggressive brain cancers, offering detailed information about genes and tumor formation. The atlas aims to advance understanding of glioblastoma biology and lead to novel approaches to improve treatment and survival.
Researchers developed a combinatorial approach to treating glioblastoma by combining three classes of anti-cancer drugs. The study found that a combination of EGFR inhibitor, PLK1 inhibitor and DNA-damaging agent effectively halted tumor growth in mouse models and human glioblastoma tissue.
The study provides a comprehensive look at glioblastoma treatments, reviewing challenges faced by researchers and clinicians. It presents hope for better treatments through harnessing the power of the human genome.
Researchers have discovered a key role played by IGFBP2 in regulating the action of EGFR in glioblastoma cells, allowing them to become resistant to drug treatments. This finding offers new hope for developing targeted therapies that target both EGFR and IGFBP2.
Scientists have identified a small RNA molecule called miR-182 that can suppress cancer-causing genes in mice with glioblastoma, a deadly type of brain tumor. The new method uses nanotechnology to deliver the microRNA across the blood-brain barrier, targeting multiple oncogenes at once and increasing cancer cell death.
Glioblastoma's aggressive nature is fueled by mTOR-induced pathways, but mTOR inhibitors have shown limited effectiveness. Compensatory glutamine metabolism plays a crucial role in mTOR inhibitor resistance, as evidenced by increased glutaminase and glutamine levels in GBM cells and tumor xenografts.
Researchers have discovered a way to boost the effectiveness of immunotherapy in treating glioblastoma by enhancing dendritic cell migration. This approach increased patient survival rates by over 36 months compared to traditional dendritic cell-based therapy alone.
Researchers at Moffitt Cancer Center have identified a key protein signaling pathway involved in the growth and survival of brain tumor stem cells. The neurotrophin pathway controls nerve growth, survival and specialization, and inhibiting TrkB and TrkC receptors can decrease stem cell survival.
A preclinical study by the University of Pennsylvania School of Medicine found engineered T cells to be both safe and effective at controlling tumor growth in mice with glioblastoma. The CAR T cells target a mutation in the epidermal growth factor receptor protein called EGFRvIII, found on about 30% of glioblastoma patients' tumor cells.
Researchers at UC San Diego identified a pyramid hierarchical network of coherent gene modules that regulate glioblastoma genes, involved in highly aggressive brain cancer. This finding informs a strategy to elucidate these modules and identify new drug therapies.
Researchers at Ohio State University identified three genes that enable glioblastoma stem-like cells to survive radiation therapy. MELK and EZH2 proteins form a complex that drives EZH2 expression, promoting tumor development and progression.
Researchers aim to eradicate glioblastomas by delivering the wound-healing peptide ACT1 to cancer cells via a virus. This approach has shown promising results in reducing tumor growth and increasing sensitivity to TMZ. The goal is to develop a novel therapy that can improve treatment outcomes for brain cancer patients.
Research shows that brain metastases have dense concentrations of tumour infiltrating lymphocytes, providing an immunoactive environment. High expression of PDL1 is common in both glioblastoma and brain metastases, making immune checkpoint inhibitors a promising treatment option.
Researchers have made a breakthrough in brain cancer treatment by identifying a key process that can be targeted with a new drug, AZD8055, which combines with Temozolomide to extend animal life by 30%. This discovery is leading to the start of a human phase I/II clinical trial as early as Spring 2015.
Researchers have discovered a fusion protein in approximately 15% of secondary glioblastomas, offering insights into the disease's cause and potential therapeutic targets. The PTPRZ-MET fusion may be exquisitely sensitive to existing MET inhibitors, allowing for personalized oncologic care.
A CTRC doctor has been awarded a $1.6 million FDA orphan grant to study the efficacy of TH-302 in treating glioblastoma, a devastating brain tumor with a median survival time of four months. The drug, combined with Avastin, aims to slow tumor growth by creating a low-oxygen environment, sparing healthy cells from chemotherapy damage.
Researchers have identified the interleukin-13 receptor ¬ chain variant 2 (IL13R¢) as a potential target for therapy in glioblastoma multiforme (GBM). Early successes of clinical trials with targeted therapies against IL13R¢ suggest increased survival time for GBM patients.
Researchers developed a new method to detect malignant brain tumors using a handheld Raman scanner, which can identify cancerous cells with high accuracy. The technique has the potential to improve surgical outcomes and reduce tumor recurrence rates.
The Translational Genomics Research Institute has received regulatory approval for a $5 million clinical trial study on glioblastoma. The pilot trial will test new drugs to extend GBM patient survival, while also analyzing genomic data from over 536 past cases and conducting lab tests to measure cell responses.
Glioblastomas are resistant to drug therapy due to epigenetic regulation of EGFR signaling, not altered DNA sequences. This finding suggests a new approach to guiding cancer therapy by analyzing the epigenetic signature of glioblastoma cells.
Scientists have successfully tested a new treatment for aggressive brain cancer, using tiny gold nanoparticles to kill tumour cells. The treatment combines chemotherapy with radiotherapy, targeting cancer cells directly and enhancing the impact of conventional treatments.
Researchers at McGill University have identified SUMO1 as a key player in the proliferation of glioblastoma tumour cells. The study reveals that sumoylation of CDK6 protein stabilizes it, enabling cancer stem cell growth and progression. This breakthrough could lead to targeted therapies for treating brain cancer.
Researchers identified a new biomarker that predicts glioblastoma response to chemotherapy temozolomide, improving patient outcomes. The biomarker targets MGMT-regulating microRNAs, which suppress the cancer-killing effect of temozolomide.
Researchers at Henry Ford Hospital identified specific genes associated with improved survival rates among patients with glioblastoma, the most deadly form of brain tumor. The study found that patients over 70 were more likely to survive longer and that gender differences played a role in short-term survival rates.
Researchers at Dartmouth's Geisel School of Medicine identified a potential therapeutic target for glioblastoma multiforme, a deadly form of brain cancer. The study found that STK17A protein is induced in response to DNA damage and is correlated with poorer outcomes.
UT Southwestern researchers found that blocking critical DNA repair mechanisms can slow down tumor growth and increase survival in glioblastoma patients. The study used a drug called NVP-BEZ235, which combined with radiation therapy significantly delayed tumor growth in mice, up to 60 days.
Researchers analyzed genomic data from The Cancer Genome Atlas and identified three molecular clusters in lower-grade brain tumors. Tumors with IDH1/IDH2 mutations and co-deletion of chromosome arms 1p and 19q have a median survival of around eight years, while those without these mutations have a median survival of only 18 months.
Researchers at Karolinska Institutet have discovered a new mechanism to kill glioblastoma cells using Vacquinol-1, which causes uncontrolled vacuolization leading to cell explosion and necrosis. This approach may lead to new cancer treatments, potentially working for other cancer diseases.
Researchers have discovered that FDA-approved anti-psychotic drugs possess tumor-killing activity against glioblastoma. The finding is based on shRNA technology that identifies genes required for glioblastoma growth and reveals surprising links to dopamine regulation, a crucial component in treating Parkinson's disease and schizophrenia.
Researchers at Ohio State University found that inhibiting the enzyme PRMT5 can significantly improve survival in an animal model of GBM. High levels of PRMT5 are associated with aggressive growth and lower overall survival rates in brain cancer patients.
Researchers at The Wistar Institute have developed a mathematical method for classifying glioblastoma tumor cells based on gene transcript variants. This system can predict the subclasses of glioblastoma tumors with 92 percent accuracy, enabling personalized therapies.
Researchers from McGill University have identified two transcription factors controlling the expression of genes involved in GBM tumourigenesis. Impairing these proteins could significantly reduce the ability of brain tumour-initiating cells to give rise to brain tumors.
A phase 2 trial of a personalized vaccine made from patient tumor tissue showed improved survival rates compared to standard care alone. The vaccine, HSPPC-96, triggered an immune response to kill remaining tumor cells after surgery.
Researchers have found that an experimental drug targeting tumor-associated macrophages decreases glioblastoma growth and extends the survival of laboratory mice with the cancer. The treatment increases rates of programmed cell death in both the macrophages and tumor cells, leading to reduced tumor proliferation and increased survival.
Researchers discovered that glioblastoma (GBM) tumor cells hide the signaling molecule targeted by therapies, adding complexity to current models of drug resistance. The findings suggest alternative approaches that could improve outcomes for cancer patients and may have significant implications for therapeutic regimens.
Researchers at Rockefeller University Press develop a novel two-pronged approach to combat glioblastoma, a highly aggressive form of brain cancer. By combining interleukin-12 with a CTLA-4 blocking drug, the cocktail successfully eradicated tumors in mice, showing promise for future treatment.
A Northwestern University research team has developed a drug that silences a critical gene in glioblastoma, increasing survival rates by nearly 20% and reducing tumor size. The novel therapeutic uses nanotechnology to target the gene, which plays a key role in therapy resistance.
The Cancer Genome Atlas has characterized the genomic abnormalities driving glioblastoma multiforme, identifying 61 new mutated genes. Detailed clinical information is available for most cases, providing a resource for researchers to develop targeted therapies.
A clinical trial suggests that combining radiotherapy with an anti-cancer drug called APG101 blocks a cell-signalling pathway crucial for glioblastoma development. The treatment showed promising results, with patients receiving the combination therapy living longer than those treated with radiotherapy alone.
Researchers at University of Texas M.D. Anderson Cancer Center discovered that an inflammatory protein converts glioblastoma cells into their most aggressive form, leading to radiation resistance and reducing treatment effectiveness. Blocking the inflammatory response may improve outcomes for patients.
Researchers at Columbia University Irving Medical Center have identified 18 new genes responsible for glioblastoma multiforme, the most common and aggressive form of brain cancer. About 15 percent of patients may be eligible for personalized treatment with existing drugs used in other cancers.
A combination of myxoma virus and rapamycin has been shown to infect and kill both brain cancer stem cells and differentiated compartments of glioblastoma multiforme, overcoming drug resistance. This study offers promising possibilities for overcoming barriers to treating the deadliest malignant brain tumor.
A Phase III study by MD Anderson Cancer Center found no overall survival (OS) or progression-free survival (PFS) benefits for bevacizumab in newly diagnosed glioblastoma patients. However, patients on bevacizumab experienced higher rates of toxicities and symptom burden compared to placebo.
A new gene panel may help personalize therapy for newly diagnosed glioblastoma patients by identifying those most likely to benefit from bevacizumab. Researchers observed a significant association between lower mesenchymal signatures and better survival in patients taking the drug.
A clinical trial found that adding bevacizumab to standard treatment for glioblastoma did not improve overall survival or progression-free survival. However, patients in the bevacizumab arm experienced a greater decline in cognitive function and symptom burden compared to those on placebo.
Researchers found that an EGFRvIII mutation alters the splicing of genes controlling cellular metabolism, enabling rapid tumor growth. The study highlights the critical role of EGFRvIII in GBM pathogenesis and provides new targets for oncogene-specific drug development.
A modified poliovirus is infecting and killing glioblastoma brain tumor cells with encouraging results in an ongoing phase 1 study, researchers report. The virus-based therapy, known as PVSRIPO, triggers the immune system to attack infected tumor cells.
Johns Hopkins researchers have discovered that mesenchymal stem cells derived from human adipose tissue can seek out and destroy glioblastoma cancer cells in the brain. This innovative approach may provide a new tool for accessing difficult-to-reach areas of the brain where cancer cells proliferate.
Researchers describe the use of 5-aminolevulinic acid (5-ALA) fluorescence to guide resection of recurrent glioblastoma multiforme, revealing a pathway of tumor spread through brain regions inaccessible to MRI. This technique increases the success of achieving maximum resection.
Researchers at Mayo Clinic identified an association between the naturally occurring enzyme Kallikrein 6 and malignant brain tumors. Higher levels of KLK6 were associated with shorter patient survival rates, but blocking its receptors made tumor cells more susceptible to treatment.